Breast Cancer prevention takes a significant leap forward as Anixa Biosciences CEO Dr. Amit Kumar unveils the company’s groundbreaking vaccine, targeting the recurrence of the most aggressive form—triple-negative breast cancer.
The development of this potentially life-saving vaccine originated at the Cleveland Clinic under the late Dr. Vincent Tuohy, who dedicated two decades to its research.
Kumar emphasized that the unique mechanism of action employed in this vaccine sets it apart from previous attempts at cancer vaccination.
The vaccine, administered in a series of three shots, has shown promise during extensive animal testing.
Following approval from the Food and Drug Administration (FDA) in 2021, human trials commenced, with Jennifer Davis becoming the first woman to undergo the vaccination series in October of the same year.
Davis, a mother of three, initially battled triple-negative breast cancer in 2018, facing aggressive chemotherapy.
Unfortunately, due to severe side effects, she had to halt the treatment prematurely to avoid long-term complications.
The ongoing trial, which includes 16 participants, has demonstrated positive results, indicating an immune response in all women.
Kumar expressed optimism, noting that the vaccine could potentially prevent recurrences and transform the landscape of breast cancer treatment.
Breast Cancer Vaccine Trials Expand
As the trial progresses, the team plans to expand the study to include hundreds of women in a double-blind study starting in 2024.
The goal is to assess the vaccine’s efficacy by comparing recurrence rates between those who receive the vaccine and those who receive a placebo.
While the focus remains on triple-negative breast cancer due to its high recurrence rate, the ultimate objective is to extend testing to other types of breast cancer.
Kumar envisions a future where this vaccine may also prevent cancer in women who have never been diagnosed.
Both Davis and Kumar, who are parents to daughters, underscored the importance of developing such a vaccine for the well-being of future generations.
Kumar believes that success in this vaccine could pave the way for similar breakthroughs in addressing other types of cancers.
Researchers from the University of Washington School of Medicine published promising findings last year on an experimental breast cancer vaccine.
The vaccine, licensed to Korean biopharmaceutical company Aston Sci, is currently undergoing a randomized Phase II study for HER2-low breast cancer.
While these developments are still in progress, the potential impact of these vaccines on breast cancer treatment and prevention is generating hope and anticipation within the scientific community.
Read Next: North Korea Launches Suspected Ballistic Missile, Japan on High Alert